Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application Gomes AQ; Martins DS; Silva-Santos BCancer Res 2010[Dec]; 70 (24): 10024-7Abundant interferon-gamma secretion, potent cytotoxicity, and major histocompatibility complex-independent targeting of a large spectrum of tumors make gammadelta T cells attractive mediators of cancer immunotherapy. However, a better understanding of the molecular mechanisms involved in tumor cell recognition and gammadelta T-cell activation is required to improve the limited success of gammadelta T-cell-mediated treatments. Here, we review key advances in basic knowledge made over the past 3 years, and summarize the results of gammadelta T-cell-based clinical trials concluded to date. We also highlight new research directions on the basis of the modulation of receptors that control the function of gammadelta T cells.|Humans[MESH]|Immunotherapy, Adoptive/*methods[MESH]|Lymphocyte Activation[MESH]|Neoplasms/*immunology/*therapy[MESH]|Receptors, Antigen, T-Cell, gamma-delta/agonists/*immunology[MESH]|T-Lymphocyte Subsets/*immunology/*metabolism[MESH] |
